Health ❯ Healthcare ❯ Clinical Trials

Drug Approval

FDA FDA Approval FDA Regulations Regulatory Affairs FDA Approvals NHS Treatments Surrogate Endpoints NHS Innovations Elinzanetant EMA Recommendations Alyftrek and Kaftrio Efficacy Studies Neurology NHS Guidelines Combination Therapy NHS ZORYVE Cream Survival Rates Blarcamesin Semaglutide FLOW Trial Kisqali EMA Eli Lilly Trials FDA Fast-Track Approval Therapeutic Goods Administration

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

The decision rests on phase 2 data showing high response rates with labeling that highlights cytokine release syndrome and neurologic risks.

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses

Modified Herpes Virus Plus Nivolumab Induces Tumor Regression in Advanced Melanoma

CDC Panel Recommends Merck’s Enflonsia Monoclonal Antibody for Babies

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer